- Home
- OIA vs ABEO Comparison
OIA vs ABEO Comparison
Compare OIA & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OIA | ABEO |
|---|---|---|
| Founded | N/A | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.7M | 280.2M |
| IPO Year | 1994 | 2005 |
Fundamental Metrics
Financial Performance| Metric | OIA | ABEO |
|---|---|---|
| Price | $5.99 | $4.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.75 |
| AVG Volume (30 Days) | 81.4K | ★ 1.3M |
| Earning Date | 01-01-0001 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ 1.01 |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,276.65 |
| Revenue Next Year | N/A | $112.53 |
| P/E Ratio | ★ N/A | $4.50 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $5.43 | $3.93 |
| 52 Week High | $6.40 | $7.54 |
Technical Indicators
Market Signals| Indicator | OIA | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 26.36 | 33.98 |
| Support Level | $5.93 | $4.00 |
| Resistance Level | $6.20 | $5.62 |
| Average True Range (ATR) | 0.05 | 0.21 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 1.28 | 10.05 |
Price Performance
Historical ComparisonAbout OIA Invesco Municipal Income Opportunities Trust
Invesco Muni Income Opps Trust operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income which is exempt from federal income tax.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.